Swiss pharma giant Roche has given itself a pricey holiday gift and deepened its oncology product portfolio with its $1.7 billion acquisition of immuno-oncology business Ignyta. Based in San Diego, the company tests, identifies, and treat patients with cancers that come with rare mutations.